{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "exchangeTimezoneName": "Europe/London", "exchangeTimezoneShortName": "BST", "currency": "EUR", "market": "gb_market", "esgPopulated": false, "gmtOffSetMilliseconds": 3600000, "exchange": "LSE", "longName": "Nanobiotix S.A.", "shortName": "NANOBIOTIX SA NANOBIOTIX ORD SH", "regularMarketPrice": 4.6, "regularMarketChangePercent": -4.153295, "messageBoardId": "finmb_20950715", "marketState": "CLOSED", "fiftyTwoWeekHighChangePercent": -0.3465909, "fiftyTwoWeekLow": 1.624, "fiftyTwoWeekHigh": 7.04, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "fiftyTwoWeekLowChange": 2.9759998, "fiftyTwoWeekLowChangePercent": 1.8325123, "fiftyTwoWeekRange": "1.624 - 7.04", "fiftyTwoWeekHighChange": -2.44, "epsTrailingTwelveMonths": -1.355, "sharesOutstanding": 19614300, "bookValue": -0.776, "fiftyDayAverage": 3.3162663, "fiftyDayAverageChange": 1.2837336, "fiftyDayAverageChangePercent": 0.3871021, "twoHundredDayAverage": 3.6809955, "twoHundredDayAverageChange": 0.91900444, "twoHundredDayAverageChangePercent": 0.24966194, "marketCap": 1006493, "priceToBook": -5.927835, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 1392278400000, "priceHint": 4, "regularMarketChange": -0.19933033, "regularMarketTime": 1683910297, "regularMarketDayHigh": 4.67756, "regularMarketDayRange": "4.52 - 4.67756", "regularMarketDayLow": 4.52, "regularMarketVolume": 46709, "regularMarketPreviousClose": 4.79933, "bid": 0.0, "ask": 0.0, "fullExchangeName": "LSE", "financialCurrency": "EUR", "regularMarketOpen": 4.6, "averageDailyVolume3Month": 12595, "averageDailyVolume10Day": 54867, "symbol": "0QAV.L"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "60 rue de Wattignies", "city": "Paris", "zip": "75012", "country": "France", "phone": "33 1 40 26 04 70", "fax": "33 1 40 26 04 44", "website": "https://www.nanobiotix.com", "industry": "", "sector": "", "longBusinessSummary": "Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.", "fullTimeEmployees": 102, "companyOfficers": [{"maxAge": 1, "name": "Mr. Laurent  Levy Ph.D.", "age": 49, "title": "Co-Founder, Pres of the Exec. Board & CEO", "yearBorn": 1973, "fiscalYear": 2022, "totalPay": {"raw": 635145, "fmt": "635.14k", "longFmt": "635,145"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Bart  Van Rhijn", "age": 49, "title": "CFO & Member of Exec. Board", "yearBorn": 1973, "fiscalYear": 2022, "totalPay": {"raw": 563444, "fmt": "563.44k", "longFmt": "563,444"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Anne-Juliette  Hermant M.A.", "age": 48, "title": "Chief People Officer & Member of Exec. Board", "yearBorn": 1974, "fiscalYear": 2022, "totalPay": {"raw": 309750, "fmt": "309.75k", "longFmt": "309,750"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Earl J. Bergey Ph.d.", "age": 67, "title": "Co-Founder", "yearBorn": 1955, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Alain  Dostie", "title": "Chief Operating Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Kathryn M. McNeil", "age": 47, "title": "Sr. VP of Investor Relations", "yearBorn": 1975, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Brandon  Owens", "title": "VP of Strategic Marketing & Corp. Communication", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Elsa  Borghi", "title": "Head of Innovation & Drug Discovery", "fiscalYear": 2019, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Sarah  Gaubert", "title": "Head of Communication & Public Affairs Department", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Patrick  Tricoli M.B.A., Pharm.D.", "title": "Global Head of Bus. Devel.", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 6, "boardRisk": 7, "compensationRisk": 10, "shareHolderRightsRisk": 7, "overallRisk": 9, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}